Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001611024-26-000002·Allogene Therapeutics, Inc.
Schedule 13G ownership disclosure
Allogene Therapeutics Inc
Common Stock · CUSIP: 019770106
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- David D. Chang, M.D., Ph.D.
Shares: 12,101,223.00 · Class: 5.2%
- Chang 2006 Family Trust
Shares: 1,201,108.00 · Class: 0.5%
- JEC 2019 Trust
Shares: 856,044.00 · Class: 0.4%
- RTC 2019 Trust
Shares: 856,044.00 · Class: 0.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001611024-26-000002
- Form type
- SCHEDULE 13G
- Filer
- Allogene Therapeutics, Inc.
- CIK
- CIK 1737287
- Filed
- Feb 13, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership